

Supplementary Materials: Differentiation, Quantification and Identification of Abrin and *Abrus precatorius* Agglutinin

Sylvia Worbs, Bettina Kampa, Martin Skiba, Eva-Maria Hansbauer, Daniel Stern, Hervé Volland, François Becher, Stéphanie Simon, Martin B. Dorner and Brigitte G. Dorner




Figure S1. Purified abrin and *A. precatorius* agglutinin (APA) analyzed by SDS-PAGE and Coomassie staining. Two μg of abrin (lane 1) or APA (lane 2) each were separated on 12% gels by SDS-PAGE under non-reducing conditions followed by staining with colloidal Coomassie Brilliant Blue over night.




Figure S2. Purified abrin and *A. precatorius* agglutinin (APA) analyzed by MALDI-TOF MS. Overview of peptide mass fingerprinting (PMF) MALDI-TOF MS spectra of approximately 600 ng of purified abrin (top) or APA (bottom) after reduction, alkylation and tryptic *in-solution* digest. Peaks are labelled with the corresponding m/z value.




Figure S3. Detection of purified abrin, APA or ricin by Western blot using the monoclonal antibodies generated in this work. Purified APA (lane 1), BSA (as negative control, lane 2), abrin (lane 3) and ricin (lane 4), each 100 ng, were separated by SDS-PAGE under reducing conditions and blotted onto PVDF membranes. For detection the indicated monoclonal antibodies were used. For development a biotin-coupled anti-mouse antibody followed by streptavidin alkaline phosphatase and CDP star as

chemiluminescent substrate were used. Exposure time of the blots was 1–10 min as indicated. As positive control the polyclonal rabbit antibody KAP142 was used in Western blotting which detected both purified *Abrus* lectins (abrin and APA, main reactivity) as well as ricin (lower signals, data not shown).




Figure S4. Binding kinetics of the newly generated monoclonal antibodies to abrin and APA. Shown are binding responses (in resonance units RU) of double referenced binding curves (red lines) overlaid with fitting curves (black lines) from a 1:1 binding model for single cycle kinetic measurements of the indicated mAbs binding to **(a)** abrin or **(b)** APA. Five increasing concentrations of abrin or APA were

injected consecutively for 120 s before buffer was injected for 600 s after injection of the highest concentration (333.33 nM corresponding to 20 µg/mL abrin or 40 µg/mL APA).




Figure S5. Binding specificity of selected monoclonal antibodies targeting the A- or B-chain of purified abrin-a. (a) 15 μ g of purified abrin-a were separated by SDS-PAGE under reducing conditions followed by staining with colloidal Coomassie Brilliant Blue overnight. H: band corresponding to non-reduced abrin-a holotoxin; B: band corresponding to B-chain of abrin-a; A: band corresponding to A-chain of abrin-a [1,2]. The assignments of the A- and B-chains were confirmed by in-gel digest followed by MALDI-TOF MS analysis. (b) Purified abrin-a was analyzed by Western blot using several monoclonal antibodies generated in this work. 100 ng of abrin-a were separated by SDS-PAGE under reducing conditions and blotted onto PVDF membranes. For detection the indicated monoclonal antibodies were used. As a positive control the polyclonal rabbit antibody KAP142 was used to detect both sub-units of purified abrin-a (A- and B-chain). For development a biotin-coupled anti-mouse antibody (for the detection of monoclonal antibodies) or a biotin-coupled anti-rabbit antibody (for the detection of KAP142) followed by streptavidin alkaline phosphatase and CDP star as chemiluminescent substrate was used. Exposure time of the blots was 15 s to 10 min as indicated.

P11140, **Abrin-a**; Protein sequence coverage: 60%

1 QDRPIK**FSTE GATSQSYKQF IEALRERLRG GLIHDI PVLP DPTTLQERNR**
 51 YITVELSNSD TESIEVGIDV TNAYVVAYR**AGTQSYFLRDA PSSASDYLET**
 101 **GTDQHSLPFY GTYGDLERWA HQSRQQIPLG LQALTHGISF FRSGGNDNEE**
 151 **KARTLIVIIQMVAEAAFRY ISNRVR**VS IQ TGTA FQPDAA MISLENNWDN
 201 LSR**GVQESVQ DTFPNQVTLT NIR**NEPVIVD SL SHPTVAVL ALMLFVCNPP
 251 NANQSPLLIR **SIVEKSKICS SRYEPTVRIG GRDGMCDVY DNGYHNGNRI**
 301 **IMWKCKDRLE ENQLWTLKSD KTIR**SNGKCL TTYGYAPGSY VMIYDCTSAV
 351 AEATYWEIWD **NGTI**INPK **SA LVLSAESSMGGTLTVQTNE YLMR**QGWR TG
 401 **NN**TSPFVTSI SGYSDLCMQA QGSNVWMADC DSNK**KEQQWA LYTDGSIRSV**
 451 **QNTNNCLTSK DHKQGSTILL MGCSNGWASQ**RWVFKNDGSI YSLYDDMVMD
 501 **VKGSDPSLKQ** IILWPYTGKP NQIWLTLF

Q06077, **Abrin-b**; Protein sequence coverage: 60%

1 QDQVIK**FTTE GATSQSYKQF IEALRQRLTG GLIHGIPVLP DPTTLQERNR**
 51 YISVELSNSD TESIEAGIDV SNAYVVAYR**AGNRSYFLRDA PTSASRYLET**
 101 **GTQQYSLRFN**GSYIDLERLA RQTR**QQIPLG LQALRHAI SF LQSGTDDQEI**
 151 **ARTLIVIIQMASEAARYRFI SYRVGVSIR**TNTAFQPDAA MISLENNWDNL
 201 SGGVQQSVQD TFPNAVTLRS VNNQPVIVDS LTHQSVAVLA LMLFVCNPPN
 251 ANQSPLLIRS **IVEKSKICSS RYEPTVRIGGRNGMCDVYD DGYHNGNRII**
 301 **AWKCKDRLEE NQLWTLKSDK TIR**SNGKCL TEGYAPGNVY MIYDCTSAVA
 351 EATYWEIWD **NGTI**INPK **SAL VLSAESSMGGTLTVQTNEY LMR**QGWR TG**N**
 401 NTSPFVTSIS GYSDLCMQAQ GSNVWLAYCDNNK**KEQQWAL YTDGSIRSVQ**
 451 **NTNNCLTSKD HKQGSPIVLM ACSNGWASQR**WLFNRNDGSIY NLHDDMVMDV
 501 **KRSDPSLKEI ILHPYHGKPN QIWLTLF**

P28590, **Abrin-c**; Protein sequence coverage: 55%

1 MDKTLKLLIL CLAWTCSFSA LRCAARTYPP VATNQDQVIK **FTTEGATSQS**
 51 **YKQFIEALRQ**RLTGGLIHDI PVLPDPTTVE ERNRYITVEL SNSERESIEV
 101 GIDVTNAYVV AYR**AGSQSYF LRDAPASAST YLFPGTQ**RYSLR**FDGSYGDL**
 151 **ERWAHQTREE**ISLGLQALTHAISFLR**SGAS NDEEKARTLI VIIQMASEAA**
 201 **RYRYISNRVG VSIR**TGTA FQ PDPAMLSLENNWDN**N**LSGGVQ QSVQDTFPN
 251 VILSSINRQP VVVDLSHPT VAVLALMLFV CNPPNANQSP LLIR**SIVEES**
 301 **KICSSRYEPT VRIGGRDGMCDVYDDGYHNGNRI IAWKCKDRLEENQLWT**
 351 **LKSDKTIR**SN GKCLTTEGYA PGNYVMIYDC TSAAEATYWEIWD**NGTI**IN
 401 PK**SALVLSAE SSSMGGTLTV QTNEYLMR**QGWR TG**N**NTSPFVTSISGYSDL
 451 CMQAQGSNVW LADCNNK**KE QQWALYTDGS IRSVQNTNNCLTSKDHKQGS**

501 PIVLMACSNG WASQRWLFKN DGS IYNLHDD MVMDVKRSDP SLKEIILHPY
 551 HGKPNQIWLTLF

Q06076, **Abrin-d**; Protein sequence coverage: 53%

1 QDQVIKFTTE GATSQSYKQF IEALRQLTG GLIHDIPVLP DPTTVEERNR
 51 YITVELSNSE RESIEVGIDV TNAYVVAYRAGSQSYFLRDA PASASTYLEP
 101 GTQRYSLRFD GSYGDLERWA HQTREEISLG LQALTHAISF LRS GASNDEE
 151 KARTLIVIIQMASEAARYRC ISNRVGVSIR TGTAFAQPDPA MLSENNWDN
 201 LSGGVQQSVQ DAFPNNVILS SINRQPVVVD SLSHPTVAVL ALMLFVCNPP
 251 NANQSPLLIR SIVEESKICS SRYEPTVRIG GRDGMCDVY DDGYHNGNRI
 301 IAWKCKDRLE ENQLWTLKSD LTIRSNKGCL TTEGYAPGNY VMIYDCTSAV
 351 AEATYWEIWDNGTIINPKSA LVLSAESSMGGTLTVQTNE YLMRQGWRTG
 401 NNTSPFVTSI SGYSDLCMQA QGSNVWLADC DNNKEQQWA LYTDGSIRSV
 451 QNTNNCLTSK DHKQGSPIVL MACSNGWASQRWLFKN DGS IYSLYDDMVMD
 501 VKGSDPSLKQ IILWPYTGKP NQIWLTLF

Q9M6E9, **Agglutinin-1**; Protein sequence coverage: 39%

1 MKFETTKNKL HGNAYYQAQF QDPIKFTTGS ATPASYNQFI DALRERLTGG
 51 LIYGIPVLRD PSTVEKPNQY VTVELSYSDT VSIQLGIDLT NAYVVAYRAG
 101 SESFFFFRNAP ASASTYLFTG TQQYSLPFDG NYDDLEKWAH QSRQRISLGL
 151 EALRQGIKFLRSGASDDEEI ARTLIVIIQMVAEAARFRYV SKLVVISLSN
 201 RAAFQPDPSML SLENTWEPL SRAVQHTVQD TFPQNVTLIN VRQERVVSS
 251 LSHPSVSALA LMLFVCNPLN ATQSPLLIRS VVEQSKICSS HYEPTVRIGG
 301 RDGLCVDVSD NAYNNGNP II LWKCKDQLEV NQLWTLKSDK TIRSKGKCLT
 351 TYGYAPGNYV MIYDCSSAVA EATYWDIWDNGTIINPKSGL VLSAESSMGG
 401 GTLTVQKNDY RMRQGWRTGNTS PFVTSIAGFFKLCMEAH GNSMWLDVCD
 451 ITKEEQQWAV YPDGSIRPVQ NTNNCLTCEE HKQGATIVMM GCSNAWASQR
 501 WVFKSDGTIYNLYDDMVMDV KSSDPSLKQI IILWPYTGNN QMWATLF

Figure S6. Protein sequence coverage of proteins identified in the purified abrin preparation. Approximately 75 µg of the purified abrin preparation used in this work were subjected to immuno-affinity enrichment using a mixture of four mAbs, namely AP430, AP3808, AP3659 and AP476, coupled to magnetic Dynabeads, followed by protein reducing, alkylation, tryptic digest and non-targeting LC-ESI-MS/MS analysis. From top to bottom, sequences of identified abrin isoforms (UniProt P11140, UniProt Q06077, UniProt P28590, UniProt Q06076) and *Abrus precatorius* Agglutinin APA; UniProt Q9M6E9) are shown after MASCOT server search against a self-assembled UniProt/NCBI database containing all abrin isoforms and *Abrus precatorius* agglutinin as well as an NCBI database containing all *Abrus precatorius* proteins. Asparagine (N) highlighted in turquoise represents potential N-linked glycosylation sites. The linker peptide sequence between the two chains of each abrin isoform is underlined. Amino acids highlighted in red were experimentally identified. Amino acids in position 1–34 in abrin-c or in position 1–20 in APA represent the signal peptide

(highlighted in grey). CAVE: Unambiguous identification of abrin-c in the presence of the other three isoforms (abrin-a, -b and -d) is not possible with our current LC-MS/MS setup-up so that no proteotypic peptides for abrin-c can be detected.

Q9M6E9, **Agglutinin-1**; Protein sequence coverage: 52%

1 MKFETTKNKL HGNAYYQAQF QDPIK **FTTGS ATPASYNQFI DALRERLTGG**
 51 **LIYGIPVLRD** PSTVEKPNQY VTVELSYSDT VSIQLGIDLT NAYVVAYR**AG**
 101 **SESSFFRNAP ASASTYLETG TQQYSLPFDG NYDDLEKWAH QSRQRISLGL**
 151 **EALRQGIKFL RSGASDDEEI ARTLIVIIQMVAEAAFRYV SKLVVISLSN**
 201 **RAAFQPDPSMLSLENTWEPL** SRAVQHTVQD TFPQNVTLIN VRQERVVVSS
 251 LSHPSVSALA LMLFVCNPLN ATQSPLLIR **SVEQSKICSS HYEPTVRIGG**
 301 **RDGLCVDVSD NAYNNGNP I I LWKCKDQLEV NQLWTLKSDK** TIRSKGKCLT
 351 TYGYAPGNVYMIYDCSSAVA EATYWDIWD **NGTIINPKSGL VLSAESSSMG**
 401 **GTLTVQKNDY** RMRQGWRTGN **DTSPFVTSIA GFFKLCMEAH GNSMWLDVCD**
 451 ITKEEQQWAV YPDGSIRPVQ NTNNCLTCEE HK**QGATIVMM GCSNAWASQR**
 501 WVFK**SDGTIY NLYDDMVMDV KSSDPSLK**QI ILWPYTGAN QMWATLF

P11140, **Abrin-a**; Protein sequence coverage: 53%

1 QDRPIK **FSTE GATSQSYKQF IEALRERLRG GLIHDIPLP DPTTLQERNR**
 51 YITVELSNSD TESIEVGIDV TNAYVVAYR **AGTQSYFLRDA PSSASDYLEFT**
 101 **GTQHSPLPFY GTYGDLELWA HQSRQQIPLG LQALTHGISF FR**SGGNDNEE
 151 KAR**TLIVIIQMVAEAAFRY ISNRVR**VSIQ TGTAQPDAA MISLENNWDN
 201 LSR**GVQESVQ DTFPNQVTLT NIR**NEPVIVD SLSHPTVAVL ALMLFVCNPP
 251 **NANQSPLLIR SIVEKSKICS SRYEPTVRIG GRDGMCDVY DNGYHNGNRI**
 301 **IMWKCKDRLE ENQLWTLKSD KTIR**SNGKCL TTYGYAPGSY VMIYDCTSAV
 351 AEATYWEIWD **NGTIINPKSA LVLSAESSSMGGTLTVQTNE YLMRQGWRTG**
 401 **NNTSPFVTSI SGYSDLQMA QGSNVWMADC DSNKKEQQWA LYTDGSIRSV**
 451 **QNTNNCLTSK DHKQGSTILL MGCSNGWASQ**RWVFKNDGSI YSLYDDMVMD
 501 **VKGSDPSLK**Q IILWPYTGKPNQIWLTLF

Q06077, **Abrin-b**; Protein sequence coverage: 54%

1 QDQVIK **FTTE GATSQSYKQF IEALRQRLTG GLIHGIPVLP DPTTLQERNR**
 51 YISVELSNSD TESIEAGIDV SNAYVVAYR GNR**SYFLRDA PTSASRYLEFT**
 101 **GTQQYSLRFN** GSYIDLERLA RQTR**QQIPLG LQALRHAI SF** LQSGTDDQEI
 151 **ARTLIVIIQMASEAARYRFI SYRVGVSIRT**NTAFQPDAA ISLENNWDNL
 201 SGGVQQSVQD TFPNAVTLRS VNNQPVIVDS LTHQSVAVLA LMLFVCNPPN
 251 **ANQSPLLIRS IVEKSKICSS RYEPTVRIGGRNGMCDVYD DGYHNGNRI I**
 301 **AWKCKDRLEE NQLWTLKSDK TIR**SNGKCL TEGYAPGNVYMIYDCTSAVA
 351 EATYWEIWD **NGTIINPKSAL VLSAESSSMGGTLTVQTNEY LMRQGWRTGN**
 401 NTSPFVTSIS GYSDLQMAQ GSNVWLAYCDNNK**KEQQWAL YTDGSIRSVQ**
 451 **NTNNCLTSKD HKQGSPIVLM ACSNGWASQR**WLFNRNDGSIY NLHDDMVMDV

501 **KRSDPSLKEI ILHPYHGKPNQIWLTLE**

Q06076, **Abrin-d**; Protein sequence coverage: 43%

1 QDQVIK**FTTE GATSQSYKQF IEALRQRLTG GLIHDIPVLP DPTTVEERNR**
 51 **YITVELSNSE** RESIEVGIDV TNAYVVAYR**AGSQSYFLRDA** PASASTYLFP
 101 GTQR**YSLRFD GSYGDLERWA HQTREEISLG** LQALTHAISF LRSASNDDEE
 151 KAR**TLIVIIQMASEAAR**YRC ISNR**VGVSIR** TGTAFAQPDPA MSLLENNWDN
 201 LSGGVQQSVQ DAFPNVILS SINRQPVVD SLSHPTVAVL ALMLFVCNPP
 251 NANQSPLLIR **SIVEESKICS SRYEPTVRIG GRDGMCDVY DDGYHNGNRI**
 301 **IAWKCKDRLE ENQLWTLK**SD LTIRSNKGKCL TTEGYAPGNY VMIYDCTSAV
 351 AEATYWEIWD **N**GTIINPKSA LVLSAESSMGGTLTVQTNE YLMRQGWRTG
 401 **NN**TSFPVTSI SGYSDLQQA QGSNVWLAD DNN**KEQQWALYTDGSIRSV**
 451 **QNTNNCLTSK DHKQGSPIVL MACSNGWASQ**RWLFKNDGSI YSLYDDMVMD
 501 **VKGS DPSLKQ** IILWPYTGKP NQIWLTLE

Figure S7. Protein sequence coverage of proteins identified in the purified APA preparation. Approximately 85 µg of the purified APA preparation used in this work were subjected to immuno-affinity enrichment using a mixture of four mAbs, namely AP430, AP3808, AP3659 and AP476, coupled to magnetic Dynabeads, followed by protein reducing, alkylation, tryptic digest and non-targeting LC-ESI-MS/MS analysis. From top to bottom, sequences of identified *Abrus precatorius* Agglutinin (APA; UniProt Q9M6E9) and three abrin isoforms (UniProt P11140, UniProt Q06077, UniProt Q06076) are shown after MASCOT server search against a self-assembled UniProt/NCBI database containing all abrin isoforms and *Abrus precatorius* agglutinin as well as an NCBI database containing all *Abrus precatorius* proteins. Asparagine (N) highlighted in turquoise represents potential N-linked glycosylation sites. The linker peptide sequence between the two chains of each abrin isoform is underlined. Amino acids highlighted in red were experimentally identified. Amino acids in position 1–20 in APA represent the signal peptide (highlighted in grey).

References

1. Herrmann, M.S.; Behnke, W.D. A characterization of abrin A from the seeds of the *Abrus precatorius* plant. *Biochim. Biophys. Acta* **1981**, *667*, 397–410, doi:10.1016/0005-2795(81)90206-3.
2. Hegde, R.; Maiti, T.K.; Podder, S.K. Purification and characterization of three toxins and two agglutinins from *Abrus precatorius* seed by using lactamyl-Sepharose affinity chromatography. *Anal. Biochem.* **1991**, *194*, 101–109, doi:10.1016/0003-2697(91)90156-n.